As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Cariprazine in the treatment of adult patients with schizophrenia. This review discusses the pharmacological properties, dosage and administration, prevention of schizophrenia relapse, and some key studies focussed on the use of Cariprazine.
Commentary is provided by Professor Nagesh Pai, Professor at The University of Wollongong and Leader of the Mental Health and the Ageing Brain Research theme at the Illawarra Health Medical Research Institute.
Please login below to download this issue (PDF)